1. Home
  2. FLNC vs EVO Comparison

FLNC vs EVO Comparison

Compare FLNC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluence Energy Inc.

FLNC

Fluence Energy Inc.

HOLD

Current Price

$19.29

Market Cap

974.7M

Sector

Miscellaneous

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.11

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNC
EVO
Founded
2018
1993
Country
United States
Germany
Employees
N/A
4766
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
974.7M
1.1B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
FLNC
EVO
Price
$19.29
$3.11
Analyst Decision
Hold
Strong Buy
Analyst Count
20
1
Target Price
$14.05
$7.00
AVG Volume (30 Days)
5.5M
259.6K
Earning Date
02-09-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,262,830,000.00
$887,396,457.00
Revenue This Year
$50.83
N/A
Revenue Next Year
$20.86
$8.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.46
$2.84
52 Week High
$25.85
$5.10

Technical Indicators

Market Signals
Indicator
FLNC
EVO
Relative Strength Index (RSI) 47.02 50.06
Support Level $18.91 $3.03
Resistance Level $21.15 $3.05
Average True Range (ATR) 2.07 0.09
MACD -0.43 0.03
Stochastic Oscillator 11.98 78.87

Price Performance

Historical Comparison
FLNC
EVO

About FLNC Fluence Energy Inc.

Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: